Increasing cultural and ethnic diversity in Alzheimer’s clinical trials is a must — but it’s going to take a complete rethinking of the way these studies are recruited, conducted, and analyzed, said a Fordham University psychology professor speaking at an Alzheimer’s conference. Read More
Meeting a final endpoint is not the only measure by which trial success should be judged, say several thought leaders in Alzheimer’s disease (AD) research; regulators should also consider any improvement along the way to a cure as clinically meaningful to patients and a valid basis for approving a drug.
With regulators and industry focused on diversity action plans, diversity, equity and inclusion (DE&I) is poised to be a huge priority this year. A recent survey reveals what is and isn’t working for sites on diversity tactics and how sponsors can best lend a hand. Read More
The clinical trials industry is increasingly turning to artificial intelligence (AI) and machine learning (ML) technologies to boost human performance and productivity and to analyze data in a way that humans simply can’t, helping research teams perform tasks more efficiently and effectively.